Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 17;22(22):12380.
doi: 10.3390/ijms222212380.

Regulation of Key Antiplatelet Pathways by Bioactive Compounds with Minimal Bleeding Risk

Eduardo Fuentes  1 , Sergio Wehinger  2 , Andrés Trostchansky  3
Affiliations
Review

Regulation of Key Antiplatelet Pathways by Bioactive Compounds with Minimal Bleeding Risk

Eduardo Fuentes et al. Int J Mol Sci. .

Abstract

Cardiovascular disease is strongly influenced by platelet activation. Platelet activation and thrombus formation at atherosclerotic plaque rupture sites is a dynamic process regulated by different signaling networks. Therefore, there are now focused efforts to search for novel bioactive compounds which target receptors and pathways in the platelet activation process while preserving normal hemostatic function. The antiplatelet activity of numerous fruits and vegetables and their multiple mechanisms of action have recently been highlighted. In this review, we review the antiplatelet actions of bioactive compounds via key pathways (protein disulfide isomerase, mitogen-activated protein kinases, mitochondrial function, cyclic adenosine monophosphate, Akt, and shear stress-induced platelet aggregation) with no effects on bleeding time. Therefore, targeting these pathways might lead to the development of effective antiplatelet strategies that do not increase the risk of bleeding.

Keywords: bioactive compounds; bleeding; hemostasis; platelet; thrombosis.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to disclose.

Figures

Figure 1
Figure 1
Antiplatelet targets of bioactive compounds without bleeding risk. In red lines: inhibition, black arrows: activation. DHM: dihydromyricetin, PCA: protocatechuic acid. SQL: tripeptide H-Ser-Gln-Leu-OH.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. McManus D.D., Freedman J.E. MicroRNAs in platelet function and cardiovascular disease. Nat. Rev. Cardiol. 2015;12:711–717. doi: 10.1038/nrcardio.2015.101. - DOI - PubMed
    1. Khodadi E. Platelet function in cardiovascular disease: Activation of molecules and activation by molecules. Cardiovasc. Toxicol. 2019;20:1–10. doi: 10.1007/s12012-019-09555-4. - DOI - PubMed
    1. MacKeigan D.T., Ni T., Shen C., Stratton T.W., Ma W., Zhu G., Bhoria P., Ni H. Updated understanding of platelets in thrombosis and hemostasis: The roles of integrin PSI domains and their potential as therapeutic targets. Cardiovasc. Hematol. Disord. Targets. 2021;20:260–273. doi: 10.2174/1871529X20666201001144541. - DOI - PubMed
    1. Gregg D., Goldschmidt-Clermont P.J. Platelets and cardiovascular disease. Circulation. 2003;108:e88–e90. doi: 10.1161/01.CIR.0000086897.15588.4B. - DOI - PubMed
    1. Jackson S.P., Nesbitt W., Westein E. Dynamics of platelet thrombus formation. J. Thromb. Haemost. 2009;7:17–20. doi: 10.1111/j.1538-7836.2009.03401.x. - DOI - PubMed

MeSH terms

Substances